Agoracom Blog Home

Posts Tagged ‘Polio’

Mountain Valley MD $MVMD $MVMDF Confirms Quicksome™ License Agreement, First Revenues $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 9:18 AM on Thursday, February 25th, 2021
This image has an empty alt attribute; its file name is MVMD-Small.png
  • Entered a commercial license agreement with that is focused on the rapidly emerging global mushroom space.
  • Based on applying MVMD’s Quicksome™ technology to mushroom nutraceutical products
  • Initial payment in the amount of $250,000 CAD

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that Mountain Valley MD Inc. (“Mountain Valley“) has finalized and entered into a commercial license agreement with Circadian Wellness Corp. (“Circadian“), a privately held Ontario corporation that is focused on the rapidly emerging global mushroom space.

The license agreement with Circadian is based on applying MVMD’s Quicksome™ technology to mushroom nutraceutical products in consideration of ongoing product royalties and an initial payment in the amount of $250,000 CAD, made up of $200,000 CAD cash and $50,000 CAD of equity shares in Circadian.  The initial payment monies will be applied to formulation, product development and sample development work and represents the Company’s first revenues.

MVMD has been working closely with Circadian on proprietary formulations for mushroom-infused products that achieved a significant increase in overall molecule efficacy with the Company’s Quicksome™ desiccated liposome technology applied across a variety of rapid dissolve oral products.  Circadian is finalizing its product plans and go-to-market strategy for a broad line of naturally derived mushroom products that will be distributed initially in North America and expanded globally in future phases.

“Embedding Mountain Valley MD’s Quicksome™ technology into our unique mushroom product formulations has allowed us to create a product line that we believe will be unmatched in its efficacy in the marketplace,” stated Dr. Sanjeev Goel, Chief Medical Officer at Circadian Wellness and founder of Peak Human Labs. “The initial consumer testing with our energy and sleep products has been very well received.  The precision of this delivery technology allows us to build the functional mushroom business out while simultaneously pursuing a leadership position in the rapidly emerging psychedelic space.”

Circadian is a privately held Ontario corporation in the business of mushroom cultivation, extraction, clinical research and development, and end-user consumer health and wellness products and retreats (www.circadianwellness.com).

“With our focus on providing our global nutraceutical, vaccine and pharmaceutical partners with unprecedented product and market advantages, we believe our partnership with Circadian Wellness is a perfect bullseye for our value proposition across the health and wellness space,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “This inroad into the rapidly growing mushroom industry timed with the broadening analyst coverage of the numerous scientific benefits of mushrooms on human health are expected to be significant for our business plan at Mountain Valley MD.”

“Our ability to drive an increase in bioavailability across convenient and easy-to-use rapid dissolve oral delivery formats provides numerous product advantages that we believe will position Circadian Wellness products as the preeminent choice for consumers in the rapidly growing mushroom marketplace,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD.

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/756066-mountain-valley-md-confirms-quicksome-license-agreement-first-revenues/messages/2305344#message

Mountain Valley MD $MVMD $MVDMF to Include Testing of South African Mutation in Upcoming COVID-19 BSL-4 Clearance Work $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 9:29 AM on Monday, February 22nd, 2021
  • Testing South African COVID-19 variant with the Company’s new solubilized Ivermectin technology.
  • Mutation is now the most dominant form of the COVID-19 virus in South Africa

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that it will be testing the new B.1.351 South African COVID-19 variant in its upcoming Bio Safety Level 4 (“BSL-4”) lab study, which is analyzing viral clearance efficacy with the Company’s new solubilized Ivermectin technology.

According to the World Health Organization*, the mutated B.1.351 COVID-19 variant is now the most dominant form of the COVID-19 virus in South Africa and is believed to be more infectious and thus easier to spread. As the COVID-19 virus continually mutates, researchers are assessing the impact of the current vaccines that are in distribution to understand if they may be rendered less effective or even noneffective**.

“We felt it was critical to look at this new South African COVID-19 variant given the immediate complexities we are seeing with the pace of vaccine rollout and the high probability that current vaccines will not be as effective, if at all, against these emerging mutations,” stated Dennis Hancock, President and CEO of Mountain Valley MD. “It is important to us across our broad human health objectives that our solubilized Ivermectin technology can be confidently applied as the broadest COVID-19 therapeutic and number one choice in the world when a vaccine falls short.”

The Company has previously communicated that it believes its solubilized Ivermectin would be suitable for a broad therapeutic across a wide range of viruses in the future, not just limited to COVID-19.

“It is not clear if the current vaccines will protect you from the new variants and early information is that vaccines are not as effective on the mutations. We are attempting in our work with the BSL-4 lab to target novel COVID-19 variants that would prove Ivermectin’s broad activity in interfering with the replication of the virus and thus broadly applies across multiple variants versus being specific to a variant the way a vaccine would be,” stated Mike Farber, Director of Life Sciences at MVMD.

As communicated in the Company’s news release on January 27, 2021, the BSL-4 trial will be the first of its kind ever conducted with human grade solubilized Ivermectin anywhere in the world and its design was led by the Company’s key scientific advisor, Dr. John Clements. Dr. Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine and has over 35 years of experience in vaccine, immunology and infectious diseases research and development, with a distinguished scientific career focused on developing and evaluating vaccines for a wide range of infectious diseases globally.

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/755796-mountain-valley-md-to-include-testing-of-south-african-mutation-in-upcoming-covid-19-bsl-4-clearance-work/messages/2304707#message

Mountain Valley MD $MVMD.ca to Commence Trading on OTCQB Market Under Ticker MVMDF $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 1:33 PM on Friday, February 12th, 2021

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) is pleased to announce that effective February 16, 2021, it will graduate from the OTC Pink Sheets (“OTCPK”) and commence trading on the OTCQB Venture Marketplace (“OTCQB”) under the symbol “MVMDF”. 

The OTCQB is operated by OTC Markets Group Inc. (“OTC”) out of New York City, NY.  The OTC operates the world’s largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies.  Trading on the OTCQB Market enables companies to efficiently build broader investor awareness and provide U.S. investors with a seamless trading facility to more easily trade through the broker of their choice.

Investors can find Real-Time quotes and market information for MVMD on www.otcmarkets.com.  The Company continues to trade on the Canadian Securities Exchange under the ticker symbol “MVMD” and the Frankfurt Stock Exchange under the ticker symbol “20MP”.

“Trading on the OTCQB is an excellent advancement that will provide a large U.S. investor base with the opportunity to participate directly in Mountain Valley MD’s growth,” stated Dennis Hancock, President and CEO of Mountain Valley MD Holdings.  “The OTC listing will contribute to our strategy to continue to enhance our share liquidity and broaden the reach and awareness of our global health and wellness innovations.”

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/755263-mountain-valley-md-holdings-to-commence-trading-on-otcqb-market-under-ticker-mvmdf/messages/2303455#message

Mountain Valley MD $MVMD.ca $MVMDF Contracts Tulane University for Adjuvant IPV Study $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 8:53 AM on Tuesday, February 2nd, 2021
  • Tulane University contracted as Research Organization to conduct its adjuvant Inactivated Polio Vaccine (“IPV“) study
  • Study will evaluate the ability of MVMD to promote dose-sparing, and therefore lower costs

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) is pleased to announce it has contracted Tulane University School of Medicine in New Orleans, Louisiana, United States, as its Contract Research Organization (“CRO“) to conduct its adjuvant Inactivated Polio Vaccine (“IPV“) study, commencing in February, 2021.

As announced in its recent news release on January 20, 2021, the Company filed a POROUS ALUMINUM NANO-STRUCTURED ADJUVANT (“PANA“) patent to support its advanced vaccine dose sparing work and began immediately to undertake the study development and contracting of a qualified CRO.  The study will compare existing Alhydrogel adjuvant to the Company’s recently invented stable nano-particulate adjuvant by both intramuscular injection and intradermal injection immunization, evaluating the antibody responses following vaccination with fractional doses of IPV comparing delivery types with IPV alone or adjuvanted.

The study is anticipated to take sixty-days and will be led by Dr. Elizabeth Norton, PhD, Assistant Professor, Department of Microbiology and Immunology at Tulane University School of Medicine.  Dr. Norton’s research focus is mucosal immunity and immunologic mechanisms of vaccination, with a particular concentration on how infection or vaccination can target specific cell populations involved in antigen transport and processing, enhance Th17 cell development and induce IgA production.

Dr. Norton was supported by the Company’s key scientific advisor, Dr. John Clements in the development and design of the adjuvant IPV study that would effectively determine the exact dose sparing achievement of its patent-pending approach.  Dr. Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine and has over 35 years of experience in vaccine, immunology and infectious diseases research and development, with a distinguished scientific career focused on developing and evaluating vaccines for a wide range of infectious diseases globally.

“Our study will evaluate the ability of MVMD’s new porous aluminum nanostructures to adjuvant injected IPV, promote dose-sparing, and therefore lower costs, and facilitate mucosal and herd immunity when compared to IPV,” stated Dr. John Clements, MVMD scientific advisor and Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine. “Successful completion of these studies and subsequent human clinical studies could further demonstrate the potential of Mountain Valley MD’s porous aluminum nanostructures as an adjuvant in a modified IPV vaccine strategy and thereby take a major step toward achieving the global eradication of polio.”

Read More:https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/754427-mountain-valley-md-contracts-tulane-university-for-adjuvant-ipv-study/messages/2301571#message